Hepatitis C virus treatment in the real world

Optimising treatment and access to therapies

Fabien Zoulim, T. Jake Liang, Alexander L. Gerbes, Alessio Aghemo, Sylvie Deuffic-Burban, Geoffrey Dusheiko, Michael W. Fried, Stanislas Pol, Jürgen Kurt Rockstroh, Norah A. Terrault, Stefan Wiktor

Research output: Contribution to journalArticle

Abstract

Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past 5 years, the launch of direct acting antiviral drugs has seen sustained virological response rates reach 90% and above for many patient groups. The new treatments are effective, well tolerated, allow for shorter treatment regimens and offer new opportunities for previously excluded groups. This therapeutic revolution has changed the rules for treatment of HCV, moving the field towards an interferon-free era and raising the prospect of HCV eradication. This manuscript addresses the new challenges regarding treatment optimisation in the real world, improvement of antiviral efficacy in 'hard-to-treat' groups, the management of patients whose direct acting antiviral drug treatment was unsuccessful, and access to diagnosis and treatment in different parts of the world.

Original languageEnglish (US)
Pages (from-to)1824-1833
Number of pages10
JournalGut
Volume64
Issue number11
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

Hepacivirus
Antiviral Agents
Therapeutics
Interferons
Hepatocellular Carcinoma
Fibrosis
Public Health
Liver
Infection

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Zoulim, F., Liang, T. J., Gerbes, A. L., Aghemo, A., Deuffic-Burban, S., Dusheiko, G., ... Wiktor, S. (2015). Hepatitis C virus treatment in the real world: Optimising treatment and access to therapies. Gut, 64(11), 1824-1833. https://doi.org/10.1136/gutjnl-2015-310421

Hepatitis C virus treatment in the real world : Optimising treatment and access to therapies. / Zoulim, Fabien; Liang, T. Jake; Gerbes, Alexander L.; Aghemo, Alessio; Deuffic-Burban, Sylvie; Dusheiko, Geoffrey; Fried, Michael W.; Pol, Stanislas; Rockstroh, Jürgen Kurt; Terrault, Norah A.; Wiktor, Stefan.

In: Gut, Vol. 64, No. 11, 01.11.2015, p. 1824-1833.

Research output: Contribution to journalArticle

Zoulim, F, Liang, TJ, Gerbes, AL, Aghemo, A, Deuffic-Burban, S, Dusheiko, G, Fried, MW, Pol, S, Rockstroh, JK, Terrault, NA & Wiktor, S 2015, 'Hepatitis C virus treatment in the real world: Optimising treatment and access to therapies', Gut, vol. 64, no. 11, pp. 1824-1833. https://doi.org/10.1136/gutjnl-2015-310421
Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G et al. Hepatitis C virus treatment in the real world: Optimising treatment and access to therapies. Gut. 2015 Nov 1;64(11):1824-1833. https://doi.org/10.1136/gutjnl-2015-310421
Zoulim, Fabien ; Liang, T. Jake ; Gerbes, Alexander L. ; Aghemo, Alessio ; Deuffic-Burban, Sylvie ; Dusheiko, Geoffrey ; Fried, Michael W. ; Pol, Stanislas ; Rockstroh, Jürgen Kurt ; Terrault, Norah A. ; Wiktor, Stefan. / Hepatitis C virus treatment in the real world : Optimising treatment and access to therapies. In: Gut. 2015 ; Vol. 64, No. 11. pp. 1824-1833.
@article{b81d38bf9f5b4ec388c5331a75ae9b03,
title = "Hepatitis C virus treatment in the real world: Optimising treatment and access to therapies",
abstract = "Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past 5 years, the launch of direct acting antiviral drugs has seen sustained virological response rates reach 90{\%} and above for many patient groups. The new treatments are effective, well tolerated, allow for shorter treatment regimens and offer new opportunities for previously excluded groups. This therapeutic revolution has changed the rules for treatment of HCV, moving the field towards an interferon-free era and raising the prospect of HCV eradication. This manuscript addresses the new challenges regarding treatment optimisation in the real world, improvement of antiviral efficacy in 'hard-to-treat' groups, the management of patients whose direct acting antiviral drug treatment was unsuccessful, and access to diagnosis and treatment in different parts of the world.",
author = "Fabien Zoulim and Liang, {T. Jake} and Gerbes, {Alexander L.} and Alessio Aghemo and Sylvie Deuffic-Burban and Geoffrey Dusheiko and Fried, {Michael W.} and Stanislas Pol and Rockstroh, {J{\"u}rgen Kurt} and Terrault, {Norah A.} and Stefan Wiktor",
year = "2015",
month = "11",
day = "1",
doi = "10.1136/gutjnl-2015-310421",
language = "English (US)",
volume = "64",
pages = "1824--1833",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Hepatitis C virus treatment in the real world

T2 - Optimising treatment and access to therapies

AU - Zoulim, Fabien

AU - Liang, T. Jake

AU - Gerbes, Alexander L.

AU - Aghemo, Alessio

AU - Deuffic-Burban, Sylvie

AU - Dusheiko, Geoffrey

AU - Fried, Michael W.

AU - Pol, Stanislas

AU - Rockstroh, Jürgen Kurt

AU - Terrault, Norah A.

AU - Wiktor, Stefan

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past 5 years, the launch of direct acting antiviral drugs has seen sustained virological response rates reach 90% and above for many patient groups. The new treatments are effective, well tolerated, allow for shorter treatment regimens and offer new opportunities for previously excluded groups. This therapeutic revolution has changed the rules for treatment of HCV, moving the field towards an interferon-free era and raising the prospect of HCV eradication. This manuscript addresses the new challenges regarding treatment optimisation in the real world, improvement of antiviral efficacy in 'hard-to-treat' groups, the management of patients whose direct acting antiviral drug treatment was unsuccessful, and access to diagnosis and treatment in different parts of the world.

AB - Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past 5 years, the launch of direct acting antiviral drugs has seen sustained virological response rates reach 90% and above for many patient groups. The new treatments are effective, well tolerated, allow for shorter treatment regimens and offer new opportunities for previously excluded groups. This therapeutic revolution has changed the rules for treatment of HCV, moving the field towards an interferon-free era and raising the prospect of HCV eradication. This manuscript addresses the new challenges regarding treatment optimisation in the real world, improvement of antiviral efficacy in 'hard-to-treat' groups, the management of patients whose direct acting antiviral drug treatment was unsuccessful, and access to diagnosis and treatment in different parts of the world.

UR - http://www.scopus.com/inward/record.url?scp=84947554940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947554940&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2015-310421

DO - 10.1136/gutjnl-2015-310421

M3 - Article

VL - 64

SP - 1824

EP - 1833

JO - Gut

JF - Gut

SN - 0017-5749

IS - 11

ER -